International Stem Cell (OTCMKTS:ISCO) Issues Quarterly Earnings Results

International Stem Cell (OTCMKTS:ISCO) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

International Stem Cell Stock Performance

ISCO traded down $0.02 on Thursday, hitting $0.31. 2,134 shares of the company were exchanged, compared to its average volume of 10,861. The firm has a fifty day simple moving average of $0.21 and a two-hundred day simple moving average of $0.18. International Stem Cell has a 12 month low of $0.12 and a 12 month high of $0.48. The stock has a market capitalization of $2.48 million, a PE ratio of -5.17 and a beta of -0.03.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.